Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study Comparing Hypnotherapy and Gabapentin for Hot Flashes.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Women with histologic confirmation of a diagnosis of infiltrating carcinoma of the breast are eligible for participation.~* Women with non-invasive or pre-invasive lesions of the breast, including but not limited to ductal carcinoma in situ (DCIS), atypical ductal hyperplasia (ADH) or lobular carcinoma in situ (LCIS) are eligible for participation.~* Women with a known breast cancer susceptibility gene (eg, BRCA) mutation or strong family history of breast cancer are eligible.~* Any woman age 60 years or more who cannot take estrogen therapy because of a real or perceived risk of developing breast cancer are eligible.~* Women under the age of 60 with a Gail model score of 1.6% or more are eligible.~* Subjective report of at least one daily hot flash.~* Able to provide voluntary informed consent.~* ≥ 18 years-old. There will be no upper limit for age inclusion.~* Karnofsky performance status \> 70%.~* Women with a history of breast cancer must have undergone treatment with curative intent.~* ≥ 4 weeks from completion of chemotherapy or radiation therapy, where appropriate.~* adequate hematopoietic function (ANC ≥ 1500/mm3; Platelets ≥ 100,000/mm3; Hemoglobin ≥ 8 g/dL)~* adequate renal and hepatic function \[Bilirubin ≤ 1.5 times upper limit of normal (ULN), serum glutamic-oxaloacetic transaminase (SGOT) ≤ 2.5x ULN, Alkaline phosphatase ≤ 2.5x ULN, and Creatinine ≤ 2x ULN\].~* No clinical evidence of disease (complete remission).~* Patients receiving neoadjuvant therapy will be eligible following completion of all adjuvant chemotherapy if indicated.~* Patients receiving hormonal therapy in lieu of or following chemotherapy will be eligible to participate.~* Patients must have access to a compact disk player.~Exclusion criteria:~* History or active secondary cancer within the last 5 years (except for superficial basal cell skin cancers).~* Any residual chemotherapy-induced CTCv3.0 Grade 2 or greater non-hematological toxicity.~* Unable to give informed consent or unable to adhere to protocol.~* Any serious medical or psychiatric illness likely to interfere with participation in this clinical study, concurrent uncontrolled illness, or ongoing or active infection will be excluded.~* Any history of alcohol or drug abuse.~* Allergy to gabapentin.~* History of seizure disorder.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Hypnotherapy (Type: EXPERIMENTAL): Patients randomized to the experimental arm were scheduled for three one-hour inductions by a single hypnotherapist, each one week apart. Standardized outlines were used for each induction. The second and third sessions also began with a standardized induction, followed by the establishment of an anchor, or physical reference point (forefinger to thumb), used to invoke images of coolness, which were individualized according to patient preference.~Patients were also instructed by the same hypnotherapist in self-hypnosis and guided imagery techniques to be used at home with the assistance of standardized audio compact disks. Participation lasted eight weeks.
- Gabapentin (Type: ACTIVE_COMPARATOR): Patients randomized to the gabapentin arm were prescribed 900mg of the drug daily (300 mg by mouth three times daily).

Based on this trial design, predict the completion outcome and termination type (if applicable).